Teva: Branded Momentum Clashes With Generic Declines And IRA Headwinds
Teva's Q4 earnings reveal significant headwinds, including declining U.S. generics revenue and rising costs in the API business, impacting overall profitability. Branded drugs like Austedo and Uzedy face challenges, with Austedo's future revenue potentially affected by IRA negotiations and tepid growth projections for Ajovy and Uzedy. Teva's experimental IBD drug, duvakitug, shows promise with positive mid-stage data, but its future hinges on successful Phase 3 trials and market competition.
Teva Pharmaceutical Industries Limited (TEVA) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference (Transcript)
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference February 24, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Eric Hughes - Head of R&D & Chief Medical Officer Vipul Jairath - Professor at Western University Conference Call Participants Umer Raffat - Evercore ISI Ash Verma - UBS David Amsellem - Piper Sandler Jason Gerberry - Bank of America Chris Schulz - J.P. Morgan Operator Good morning or good afternoon all, and welcome to the Duvakitug Anti-TL1A Phase 2b Data Presentation from ECCO.
Final Trade: TEVA, JNJ, TJX, BABA
The final trades of the day with the Fast Money traders.
Teva Pharm CEO calls for faster US generic drug approvals
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding freezes, the CEO of Israel's Teva Pharmaceutical Industries said on Monday.
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceuticals Industries Ltd NYSE: TEVA is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also has a line of branded drugs driving growth.
Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity
Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be outperformed, and a desirable entry point for long-term investors. Teva Pharmaceutical's pipeline, including Duvakitug and multiple biosimilars, offers significant growth prospects, with several key Phase 3 milestones and potential launches from 2025 to 2027.
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
Teva stock falls 14% despite better-than-expected fourth-quarter earnings results due to a weak 2025 outlook.
Why Teva Pharmaceutical Stock Is Sinking Today
Shares of Teva Pharmaceutical Industries (TEVA -13.21%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m.
Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 1% on Wednesday.
Teva Pharma CEO: Guidance based on the new Teva that grows every year
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, drug price negotiations, and much more.
Teva Pharmaceutical Industries Limited (TEVA) Q4 2024 Earnings Conference Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q4 2024 Earnings Conference Call January 29, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric Hughes - Head of R&D & Chief Medical Officer Eli Kalif - CFO Conference Call Participants Umer Raffat - Evercore ISI Jason Gerberry - Bank of America David Amsellem - Piper Sandler Balaji Prasad - Barclays Ash Verma - UBS Yifeng Liu - HSBC Glen Santangelo - Jefferies Chris Schulz - J.P. Morgan Operator Hello, and welcome to the Fourth Quarter and Full-Year 2024 Teva Pharmaceutical Industries Earnings Conference Call.
Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
